Navigation Links
Nektar Announces that FDA Grants Fast Track Designation to Etirinotecan Pegol (NKTR-102) for the Treatment of Metastatic Breast Cancer
Date:11/7/2012

cerMore than one million people worldwide are diagnosed with breast cancer globally every year. (1)  The chance of developing invasive breast cancer at some time in a woman's life is a little less than one in eight (12%).  There are approximately 200,000 new cases of breast cancer in the United States and 430,000 in Europe each year. (2)  Metastatic breast cancer refers to cancer that has spread from the breast to distant sites in the body. 

Anthracyclines and taxanes (AT) are the most active and widely used chemotherapeutic agents for breast cancer, but the increased use of these agents at an early stage of disease often renders tumors resistant to these drugs by the time the disease recurs, thereby reducing the number of treatment options for metastatic disease. Drugs used to treat patients who progress following AT treatment can have response rates of 20-30%; however, resistance develops rapidly and new agents with different mechanisms of action, such as topoisomerase I inhibitors, are needed that have the potential to overcome the problem of drug resistance to prior therapies. (3)  There are currently no FDA-approved topoisomerase I inhibitors to treat breast cancer.

About NektarNektar Therapeutics is a biopharmaceutical company developing novel therapeutics based on its PEGylation and advanced polymer conjugation technology platforms. Nektar has a robust R&D pipeline of potentially high-value therapeutics in oncology, pain and other therapeutic areas. In the area of pain, Nektar has an exclusive worldwide license agreement with AstraZeneca for naloxegol (NKTR-118), an investigational drug candidate, which is being evaluated in Phase 3 clinical studies as a once-daily, oral tablet for the treatment of opioid-induced constipation.  This agreement also includes NKTR-119, an earlier stage development program that is a co-formulation of naloxegol and an opioid.  NKTR-181, a novel mu-opioid analgesic can
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Nektar to Announce Financial Results for the Third Quarter of 2012 On Tuesday, November 13, 2012, After Close of U.S.-Based Financial Markets
2. Nektar Therapeutics President and CEO, Howard W. Robin, To Present at the UBS 2012 Global Life Sciences Conference in New York City
3. Nektar Therapeutics Reports Financial Results for the Second Quarter of 2012
4. Nektar Announces Initiation of Investigator-Sponsored Trial Evaluating Etirinotecan Pegol (NKTR-102) in Patients with Bevacizumab (Avastin)-resistant High-Grade Glioma
5. Nektar Announces Start of Enrollment in Phase 2 Study of NKTR-181, a Novel Opioid Analgesic Molecule, for Treatment of Chronic Pain
6. Nektar Announces that FDA Grants Fast Track Designation to NKTR-181, a New Oral Opioid Analgesic Molecule, for the Treatment of Moderate to Severe Chronic Pain
7. Nektar Therapeutics President and CEO Howard W. Robin to Present at the Jefferies 2012 Global Healthcare Conference in New York
8. Nektar Therapeutics Reports Financial Results for the First Quarter of 2012
9. Nektar to Announce Financial Results for the First Quarter of 2012 on Wednesday, May 2, 2012, After Close of U.S.-Based Financial Markets
10. Life Technologies Announces Next-Gen Digital PCR Instrument Designed for Widespread Adoption
11. Blue Belt Technologies Announces First United Kingdom-Based NavioPFS Unicondylar Knee Replacement Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... Neurelis, Inc. ("Neurelis") today announced an agreement ... held by Biotie to purchase Neurelis, clearing the way ... diazepam) for pediatric and adult epilepsy patients who experience ... Biotie has advanced the development program for NRL-1 and ... work required for NDA submission to the FDA.  Given ...
(Date:7/10/2014)... July 10, 2014  Breg, Inc., a premier ... launched the FreeRunner™ knee brace with new innovations ... patella mal-tracking return to active lifestyles.  FreeRunner,s patent-pending ... braces, providing support when patients need it most, ... don,t. Patellofemoral issues are the most ...
(Date:7/10/2014)... , July 10, 2014  BC Technical, the ... MiE America , Inc., a leading provider of ... into a long-term agreement naming BC Technical as the ... MiE and BC Technical announced today ... to establish BC Technical as the service and systems ...
Breaking Medicine Technology:Neurelis Regains Rights to Intranasal Diazepam Program 2Neurelis Regains Rights to Intranasal Diazepam Program 3Breg Introduces Knee Brace to Help Runners with Patellofemoral Pain Syndrome 2BC Technical Partners With MiE America To Be Authorized Provider Of Systems & Service 2
... 20, 2011 Ann Arbor SPARK recently celebrated the conclusion ... and a reception.  At the Ann Arbor SPARK Boot Camp ... Boot Camp" winner, based on the quality of its investor ... engagement though the Ann Arbor SPARK Business Accelerator.   ...
... HYDERABAD, India, May 20, 2011 Neuland Laboratories Ltd., ... (APIs), complex intermediates, and contract research and manufacturing services ... results for the 2011 fiscal year (FY) ended March ... report that in fiscal year 2011, Neuland delivered on ...
Cached Medicine Technology:Brio Device Awarded Best of Ann Arbor SPARK's Boot Camp 2Neuland Labs Reports Financial Results for Fiscal Year 2011 2
(Date:7/13/2014)... 2014 A Xarelto lawsuit webpage ... to provide consumers with the most current information regarding ... the blood-thinning medication, as well as the growing ... around the country. The law firm is now offering ... from life-threatening internal bleeding and related complications while using ...
(Date:7/13/2014)... Hope Palliative & Hospice Care announced today that they ... Tamarack Senior Living Community in Palatine, IL. The group, called ... 3rd Wednesdays of every month. This group will begin ... at 55 S. Greeley St. Palatine, IL 60067. It ... cost for the group. , “A grief support group ...
(Date:7/13/2014)... Wa (PRWEB) July 13, 2014 According ... by Vkool.com, this is a comprehensive guide that features ... deal with KP (keratosis pilaris). This guide ... 1: What Is Keratosis Pilaris? ,     Chapter 2: ... I Know If I Have KP? ,     Chapter ...
(Date:7/12/2014)... Recently, Fadhits.com, a well-known wedding dress manufacturer and ... graduation dresses to its product line. In addition, the ... It wants to bring more benefits for its loyal fans. ... discounted prices, up to 72% off. , As a leader ... Its online shop is a good place for ladies who ...
(Date:7/12/2014)... The Passenger Information System market is ... $20,341.36 million by 2019, at an expected CAGR of ... The public transport infrastructure in North America is well ... almost every corner of the region. The growing ridership ... transport service providers are driving the North American Passenger ...
Breaking Medicine News(10 mins):Health News:Xeralto Lawsuit Page Launched By Wright & Schulte LLC To Provide Information On Potential For Xarelto Bleeding Side Effects, Growing Litigation 2Health News:Xeralto Lawsuit Page Launched By Wright & Schulte LLC To Provide Information On Potential For Xarelto Bleeding Side Effects, Growing Litigation 3Health News:Xeralto Lawsuit Page Launched By Wright & Schulte LLC To Provide Information On Potential For Xarelto Bleeding Side Effects, Growing Litigation 4Health News:Hope Hospice Announces Grief Support Group at the Tamarack Senior Living Community 2Health News:Living With KP Book Review Exposes Jennifer Richards' Keratosis Pilaris Guide – Vkool.com 2Health News:Living With KP Book Review Exposes Jennifer Richards' Keratosis Pilaris Guide – Vkool.com 3Health News:New Collection of Long Graduation Dresses Revealed by Fadhits.com 2Health News:North America Passenger Information System (ICT) Market worth $5,486.88 Million by 2019 - New Report by MicroMarket Monitor 2Health News:North America Passenger Information System (ICT) Market worth $5,486.88 Million by 2019 - New Report by MicroMarket Monitor 3Health News:North America Passenger Information System (ICT) Market worth $5,486.88 Million by 2019 - New Report by MicroMarket Monitor 4
... Yingxia,International, Inc. (OTC Bulletin Board: CYXI) ("China Yingxia" ... industry engaged in the,development, manufacture and distribution of ... in the People,s Republic,of China ("PRC"), today reported ... 31, 2008., First Quarter 2008 Highlights, ...
... goal of tailoring cancer treatment for each individual, researchers ... suggesting a simple blood test can help doctors more ... cancer. , It can take several weeks and sometimes ... working because it can take that long to observe ...
... protein called IGF-1R in patients with gastrointestinal stromal tumors ... responsive to the drug imatinib mesylate (known as Gleevec), ... the Fox Chase Cancer Center in Philadelphia. Preliminary ... might respond well to agents in development for treatment-resistant ...
... Digital Power,Corporation (Amex: DPW ) (herein "Digital Power") ... March 31, 2008., Digital Power reported revenue of ... of 15.6% from $2,742,000 for the same quarter,last year. ... of 2008 was,reported, compared to an operating profit of ...
... 15 /Xinhua-PRNewswire-FirstCall/ -- Genesis,Pharmaceuticals Enterprises, Inc. (OTC Bulletin ... company with its principal operations,in the People,s Republic ... quarter ended March 31, 2008, the Company,s third ... A 10QSB Form was filed for the quarter,with ...
... Alexza,Pharmaceuticals, Inc. (Nasdaq: ALXA ) announced today ... Vice President, Quality. He will have,responsibilities in the ... manufacturing operations and preclinical / clinical,product candidates. Mr. ... at Telik, Inc. in Palo Alto, California, where ...
Cached Medicine News:Health News:China Yingxia International, Inc. Reports First Quarter 2008 Results 2Health News:China Yingxia International, Inc. Reports First Quarter 2008 Results 3Health News:China Yingxia International, Inc. Reports First Quarter 2008 Results 4Health News:China Yingxia International, Inc. Reports First Quarter 2008 Results 5Health News:China Yingxia International, Inc. Reports First Quarter 2008 Results 6Health News:China Yingxia International, Inc. Reports First Quarter 2008 Results 7Health News:China Yingxia International, Inc. Reports First Quarter 2008 Results 8Health News:China Yingxia International, Inc. Reports First Quarter 2008 Results 9Health News:Study suggests blood test can help improve treatment outcomes for breast cancer patients 2Health News:Protein predicts Gleevec resistance in gastrointestinal tumors 2Health News:Digital Power Reports Financial Results for the First Quarter Ended March 31, 2008 2Health News:Digital Power Reports Financial Results for the First Quarter Ended March 31, 2008 3Health News:Genesis Pharmaceuticals Reports Results for the Third Quarter of Fiscal Year 2008 2Health News:Genesis Pharmaceuticals Reports Results for the Third Quarter of Fiscal Year 2008 3Health News:Genesis Pharmaceuticals Reports Results for the Third Quarter of Fiscal Year 2008 4Health News:Genesis Pharmaceuticals Reports Results for the Third Quarter of Fiscal Year 2008 5Health News:Genesis Pharmaceuticals Reports Results for the Third Quarter of Fiscal Year 2008 6Health News:Genesis Pharmaceuticals Reports Results for the Third Quarter of Fiscal Year 2008 7Health News:Genesis Pharmaceuticals Reports Results for the Third Quarter of Fiscal Year 2008 8Health News:Genesis Pharmaceuticals Reports Results for the Third Quarter of Fiscal Year 2008 9Health News:Genesis Pharmaceuticals Reports Results for the Third Quarter of Fiscal Year 2008 10Health News:Genesis Pharmaceuticals Reports Results for the Third Quarter of Fiscal Year 2008 11Health News:Genesis Pharmaceuticals Reports Results for the Third Quarter of Fiscal Year 2008 12Health News:Carlos A. Parra Joins Alexza Pharmaceuticals as Vice President, Quality 2
The Pach IV is the premier product for cornea thickness measurement in conjunction with Glaucoma screening....
Inquire...
... Immunosorbent Assays(ELISA) is intended for the detection ... Measles Rubeola) virus in human sera. Individual ... determination of immune status. Paired sera, acute ... or a significant rise in antibody as ...
Measles IgM ELISA test is an enzyme linked immunosorbent assay (ELISA) for the detection of IgG class antibodies to Measles (Rubeola) in human serum or plasma....
Medicine Products: